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Abstract 
This study compared the success rates of buprenorphine and clonidine 
in detoxification of heroin-dependents and evaluated the recurrence of 
drug abuse in patients taking naltrexone in a 6 month follow up. 
Background: 
A double-blind study was carried out in Kerman’s psychiatric hospital 
on heroin-dependents seeking detoxification during the years 2007-
2009.These patients were randomized into 2 groups receiving clonidine 
and buprenorphine. The success rate of detoxification was evaluated at 
the end of the trial and each patient was discharged with a daily 
consumption of 25 mg naltrexone. They were monitored for 6 months 
with respect to naltrexone consumption and withdrawal from drug 
abuse. 
Methods: 
Overall 49 patients participated in the study. The success rate of 
detoxification with naltrexone was confirmed in all subjects. In the group 
receiving clonidine, 2 subjects (9.5%) had a clinical opiate withdrawal 
scale (COWS) above 12 in day 5 (P = 0.186) and none of the subjects in 
the group taking buprenorphine had a COWS above 12 in day 5. The signs 
and symptoms of withdrawal and the desire for substance abuse was 
declined significantly in both groups over time; 19% of subjects detoxified 
with clonidine and 39% detoxified with buprenorphine continued taking 
naltrexone for one month and 52% detoxified with clonidine and 53.5% 
detoxified with buprenorphine entered the maintenance treatment. The 
average days remaining in treatment and being free of recurrence of drug 
abuse was not significantly different between the two groups in a 6 month 
follow-up. 
Findings: 
Administration of buprenorphine within a few days was more efficient 
in reducing the signs and symptoms of withdrawal when compared to 
clonidine. However, recurrence of drug abuse was not significantly 
different between the two groups. 
Conclusion: 
Clonidine, Buprenorphine, Naltrexone, Heroin withdrawal, 
Recurrence. 
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Introduction  
The prevalence of addiction to heroin and other 
drugs has increased significantly in the recent 
years. According to official statistics, the number 
of opioid addicts ranged from 1,200,000 to 
2,000,000 in Iran, although non-official statistics 
estimated a total of 4,000,000.1 At this time our 
country has the most opiate substance users in the 
world.2 Detoxification is the first step in treating 
these patients. Various methods are used in 
opioid detoxification in the recent years. Alpha 
adrenergic agonists such as clonidine act on locus 
coeruleus nucleus and suppress the overwork of 
adrenergic system in the detoxification phase, 
however they produce side effects including 
hypotension, dizziness, drowsiness, nausea, 
vomiting, xerostomia (dry mouth) and do not 
completely eradicate the symptoms of 
withdrawal.3,4 It is speculated that clonidine is 
responsible for the death of two heroin-
dependent patients which necessitated close 
observation and limitation in the use of this drug.5 
The use of opioid agonists such as methadone 
also has limitations due to the death risks 
associated to its overuse and uncontrolled 
consumption.6,7 Buprenorphine is a semi-synthetic 
thebaine derivative with partial agonist actions at 
the Mu opioid receptor and weak antagonist 
actions at the kappa opioid receptors. It has 
certain advantages over methadone such as lower 
death risk due to overdose and lower respiratory 
depression.6-8 Roughly, all the bioavailability of 
oral buprenorphine is eliminated due to very high 
first pass metabolism and therefore, 
buprenorphine as detoxificant is administered as 
liquid solution or sublingual tablet containing 
buprenorphine alone or in conjunction with 
naloxone 1:4. The latter form has a lower risk of 
substance abuse with IV injection and lower 
associated side effects such as AIDS and hepatitis 
transmission in heroin-dependents.8,9 The initial 
elimination of buprenorphine takes place in 3-5 
hours and the final elimination has a half-life of 
over 24 hours and is slowly released from the 
receptor making it possible for an every other day 
administration.10 In October 2002, the food and 
drug administration (FDA) approved subutex 
and suboxone sublingual tablets for this 
purpose.10-12 
Effective monitoring of signs and symptoms of 
withdrawal is a crucial step in preventing the 
recurrence of drug abuse and should begin in 6 to 
8 hours after the last usage of drug. 
Buprenorphine, as a control for withdrawal 
symptoms, is used in dose-tapering regimens 
over a few weeks or shorter periods such as 7 to 
10 days, all of which had desirable clinical 
outcomes and therefore, make it difficult to select 
a regimen with minimum effective 
buprenorphine.13 With respect to the growing 
number of opioid abusers and its adverse 
consequences for health care units and other 
social services, the use of a detoxification method 
along with the best control of withdrawal 
symptoms, lower side effects. Lower period, 
lower amount of drugs and higher reliability 
seem to be necessary. Therefore, the present study 
as a randomized, double-blind clinical trial, 
evaluated the impact of sublingual buprenorphine 
and clonidine in controlling the signs of heroin 
withdrawal in a short-term period, to compare 
the efficacy of sublingual buprenorphine and 
clonidine in controlling the symptoms of heroin 
withdrawal and to assess recurrence in a 6-month 
maintenance treatment using naltrexone 
following detoxification. 
 
Methods 
This study, as a double-blind clinical trial, was 
carried out on a group of opioid-dependent 
patients seeking detoxification admitted to 
Kerman's Shaid Beheshti hospital (in the south-
east of Iran) from the year 2007 till 2009. This 
study was conducted with the support of the 
neuroscience research center. Participants were 
men aged 18 to 40 years and were diagnosed with 
opioid-dependent according to the DSM IV 
criteria14 having their first visit for detoxification. 
Exclusion criteria included acute hepatitis, liver 
disease (SGOT > 50), diabetes, acute psychotic 
disease, personality disorder, concomitant abuse 
of methadone, beta-blockers, and calcium channel 
blockers, any medical condition interfering with 
clonidine such as cardiovascular disease, renal 
disease and finally, a history of allergy to 
clonidine, buprenorphine and naltrexone. In 
addition, patients with a blood pressure below 
90/60 and a pulse below 60 per min during 
treatment were excluded from the study. Patients 
were able to read and write the questionnaire and 
were thoroughly informed before being placed 
into two groups. After signing a written consent 
form, they were put in either of the two 
detoxification groups, clonidine and 
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buprenorphine, using randomization method. To 
ensure ethical principles, the ethical committee of 
Kerman's neuroscience research center devoted 
the code K/87/2 to this study. Initially, 50 
patients seeking addiction therapy were 
evaluated, from which, 15 subjects were excluded 
due to lack of participation criteria or 
unwillingness to participate and an overall 35 
subjects entered the study. Psychiatric interview, 
clinical examination and medical history taking 
were done by the psychiatric resident. CBC tests, 
kidney and liver function tests, hepatitis and HIV 
tests were also obtained. In order for the 
researcher and patient to be unaware of the type 
of therapy, the placebo of each drug was given in 
the other drug group and each drug was assigned 
with a code, kept by a third party not involved in 
the study. The first group received sublingual 
buprenorphine hydrochloride, 2 mg tablets, and 
the placebo of clonidine and the second group 
received clonidine and the placebo for 
buprenorphine. In group one oral clonidine 
placebo tablets and buprenorphine were 
administered 2, 4, 6, 4 and 2 mg/day during days 
1 to 5, respectively. In some cases, depending on 
the severity of symptoms, a 2-4 mg 
buprenorphine was added in the withdrawal 
phase.15-17 In group two, oral clonidine, 0.2 mg 
tablets, and sublingual buprenorphine placebo 
were administered in days 1 to 5 with one tablet 
twice in the first day, one tablet three times in the 
second and third days, one tablet in the fourth 
day and one tablet in the fifth day and if 
indicated, 0.2 0.4 mg/day additional drug was 
administered.10,18 The placebo for both drugs was 
provided by the pharmacology department of 
Kerman University of Medical Sciences. 
Vital signs were controlled four times a day. 
Also, before administration of each dosage, the 
patient was monitored by the nurse and 
physician for appearance of side effects. 
The main outcomes investigated in this study 
included the clinical opiate withdrawal scale 
(COWS) above 12 in day 5, the success rate of 
detoxification with naltrexone two days after the 
end of detoxification phase, the rate of remaining 
in treatment with naltrexone in a 6-month 
monitoring period and also, the rate of positive 
urinary samples for opioids at the end of 6 
months. The intensity of signs and symptoms of 
withdrawal in the detoxification phase and the 
desire for substance abuse were also evaluated in 
these patients. In order to assess the intensity of 
signs, the COWS was applied which consists of 11 
items (each item having 0 to 4 or 5 points). A total 
of 5-12 points indicate a weak withdrawal sign, 
13-24 stand for moderate withdrawal sign, 25-36 
show moderate to severe withdrawal sign and 
points above 36 demonstrate a severe withdrawal 
sign.19-20 The intensity of psychiatric withdrawal 
signs was evaluated using the adjective rating 
withdrawal scale (ARWS) consisting of 16 items 
rated 0 to 9 by the patient.21 The desire for 
substance abuse was assessed using a visual 
analogue scale (VAS) in which a 10 cm line was 
marked by the patient indicating the desire for 
substance abuse. One end indicated lack of 
interest for substance abuse and the other end 
indicated the highest desire for substance abuse.22 
COWS questionnaire was filled out by the 
psychiatric technician at 9 AM in days 1, 2, 3 and 
5 and the ARWS questionnaire was filled out by 
the patient. 
Vital signs were controlled four times a day 
and before administration of each drug dose, and 
the patient was evaluated by physician and nurse 
for appearance of side effects according to various 
references. Urine test for opioid substance was 
performed using thin layer chromatography. To 
ensure the success of detoxification, patients were 
administered naltrexone two days following 
detoxification and then, discharged with 
administration of naltrexone 25 mg/day for 6 
months. They were monitored every 2 months by 
questioning the patient and his/her family on the 
phone in terms of continuing the use of 
naltrexone and maintaining the treatment. In 
cases of contradiction between the statements of 
patient and his/her family, the family was 
considered to be the main reference. 
It should be noted that the validity and 
accuracy of self-proclaimed statements expressed 
in different studies are dependent on the 
confidentiality of the data and that the data 
should be collected in a safe place within 
acceptable limits.23 Previous studies indicated the 
accuracy of self-proclaimed data in Iran.24 
Monitoring was completed at the 6th month in 
person through obtaining urine tests. In cases of 
controlling withdrawal symptoms, trazodone, 
lorazepam, hydroxyzine, acetaminophen and 
hyoscine were used. 
In order to compare nominal and numerical 
variables, chi-square test, fisher’s exact test and  
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t-test were utilized. For comparing the average 
deprivation score between the two groups in 
consecutive days repeated measure ANOVA was 
applied. 
 
Results 
There was no significant difference between the 
two groups in terms of basic variables (except 
marital status) (table 1). Overall, the frequency of 
signs and symptoms of withdrawal either 
psychiatric or objective were significantly 
declined from the 3rd day in both groups. 
Changes in the average COWS, ARWS and 
desire for substance abuse are presented in table 
2 and the average days remaining in treatment 
and also the average days of naltrexone 
consumption in the group receiving clonidine 
and buprenorphine are presented in table 3. In 
the group receiving clonidine, 2 (9.5%) subjects 
had a COWS above 12 in day 5 and none of the 
subjects in the group receiving buprenorphine 
had an average COWS above 12 in the 5th day  
(P = 0.186). All patients took naltrexone at the 
end of the detoxification period. Clonidine was 
discontinued in the 3rd day in 2 patients of the 
group receiving clonidine due to blood pressure 
below 90/60; and one patient complained of 
dizziness. In the group receiving buprenorphine, 
no significant side effect was observed except in 
one patient experiencing euphoria. According to 
the personal and family statements and with 
confirmation of urine test, one patient 
maintained withdrawal in the 6 months 
monitoring after detoxification and discharge. In 
the group receiving buprenorphine, 3 subjects 
completed the treatment for 6 months and only 
one visited for urine test which was confirmed 
with a negative test result. 
 
Table 1. Comparison of some of the variables in two therapeutic groups receiving clonidine and buprenorphine 
 
Variables Clonidine group Buprenorphine group P value 
Mean age (±SD) 28.4 (45) 26.3 (5.7) 0.178 
Average consumption (g) (±SD) 3.1 (1.0) 3.5 (2.0) 0.06 
Average years of consumption 9.1 (4.3) 6.9 (4.1) 0.08 
Illiterate or elementary education (%) 
Higher (%) 
19 (90.5) 
27 (96.4) 
2 (9.5) 
1 (3.6) 
0.629 
Marriage Status             Single 
                  Married (%) 
7 (33.3) 
14 (66.7) 
20 (71.4) 
8 (28.6) 
0.0008 
Occupational Status      Employed (%) 
                                       Jobless (%) 
16 (67.9) 
5 (32.1) 
19 (71.4) 
9 (28.6) 
0.523 
 
Table 2. Comparison of the trend of changes in COWS, ARWS and craving in two groups receiving clonidine and 
buprenorphine 
 
Variables Types First day Second day Third day Fifth day P value 
Within groups Between 
groups 
COWS* Clonidine 12.6 (1.3) 19.3 (1.5) 16.8 (2) 5.7 (1.0)  
< 0.001 
 
< 0.001 Buprenorphine 7.1 (1.0) 13.3 (1.3) 10.5 (1.2) 1.7 (0.4) 
ARWS** Clonidine 52.7 (3.0) 62.3 (4.1) 62.4 (6.3) 34.1 (1.8)  
< 0.001 
 
< 0.012 Buprenorphine 43.4 (2.8) 53.5 (3.0) 48.2 (3.2) 24.1 (1.8) 
Craving*** Clonidine 96.2 (1.1) 88.1 (2.1) 81.0 (3.1) 67.5 (3.5)  
< 0.001 
 
< 0.004 Buprenorphine 89.2 (1.8) 76.2 (2.8) 68.5 (3.1) 55.1 (3.0) 
*Consisting of 11 items each having 0 to 5 points. 
**Consisting of 16 items each having 0 to 9 points. 
***Using the VAS scale in which the total score can be between 0 to 100 points. 
 
Table 3. The average days remaining in treatment and the average days of naltrexone consumption in 
the two groups receiving clonidine and buprenorphine in a 6-month follow-up 
 
Drug group Naltrexone 
consumption 
P value Remaining in 
treatment 
P value 
Clonidine 32.5 (10.3) 0.741 70.2 (17.4) 0.958 
Buprenorphine 31.6 (10.9) 66.7 (17.9) 
 
Buprenorphine and Clonidine in Detoxification of Heroin-Dependents Ziaaddini et al 
22 Addict & Health, Winter & Spring 2010; Vol 2, No 1-2. 
Table 4. The frequency distribution of Naltrexone consumption in the two groups receiving 
buprenorphine and clonidine 
 
Drug group 
 
Naltrexone consumption 
Clonidine Buprenorphine 
frequency percent frequency percent 
Still remaining  
Not remained 
Not access to patient 
4 
13 
4 
19 
62 
19 
11 
12 
5 
39 
43 
18 
 
Table 5. The frequency distribution of the number of subjects who remained in treatment in the two groups 
 
Drug group 
Remaining in treatment 
Clonidine Buprenorphine 
frequency percent frequency percent 
Patients continued treatment 
Patients did not continue treatment 
Not access to patient 
11 
5 
5 
52 
24 
24 
15 
7 
6 
53.5 
25 
21.5 
 
Discussion 
This investigation showed that administration of 
buprenorphine for a few days can not only be as 
effective as clonidine in controlling the signs and 
symptoms of withdrawal from heroine, it is 
significantly superior to clonidine in that respect.  
On the other hand, a comparison between the 
findings of the current study with those of other 
investigations concerning heroine withdrawal 
indicates the high success rate of buprenorphine 
in detoxification. Niagam et al and Cheskin et al 
also15, reported the superiority of buprenorphine 
to clonidine in controlling the signs and 
symptoms of withdrawal from opioids. Gowing 
et al found that buprenorphine was more effective 
in eliminating the signs of withdrawal compared 
to clonidine or lofexidine and patients completed 
the detoxification period more effectively. 
Although there was no significant difference in 
the appearance of side effects with these drugs, it 
seems that more patients abandoned the study 
due to side effects in the group receiving 
clonidine.25 In contrast, Telias et al5 reported a 
success rate of 73% in 82 subjects in detoxification 
and withdrawal at the end of a 10-day 
detoxification period detoxified with 
buprenorphine and 81% in 32 subjects detoxified 
with clonidine, although buprenorphine was 
more accepted by patients. The difference with 
the results of the present study may be due to 
different number of samples, consumption of 
opioids with stronger effects, and differences in 
detoxification periods during regimens and also, 
different drug metabolism in subjects. A study 
performed on 4 detoxification groups (outpatient 
and inpatient buprenorphine and outpatient and 
inpatient clonidine) showed that inpatients 
received buprenorphine had a better chance of 
following the therapy compared to those received 
clonidine and compared to the outpatients. Also, 
they had milder signs of withdrawal and better 
maintenance in treatment.23 Therefore, the current 
study was performed on patients admitted to the 
hospital. The prevention of recurrence of drug 
abuse is a crucial step following detoxification 
which is achieved by drug or non-drug methods, 
independent or combined. Due to the wide range 
of social workers and substance abuse and its 
legal consequences, studies on the efficacy of 
these methods are different in various 
communities and do not have a certain criteria.9 
The excessive desire for drug abuse is related to 
the euphoria caused by opioids which is 
mediated by the mu receptors. 
Naltrexone, an antagonist of the mu receptor, 
is approved by the united states FDA for 
treatment of alcohol dependence and blockade of 
the effects of opioids.9,26 In the present study, 19% 
of the subjects detoxified with clonidine and 34% 
subjects detoxified with buprenorphine continued 
taking naltrexone for one month. Although this 
difference was considerable, it was not 
statistically significant and it may be related to 
better family support and better personal skills in 
dealing with stress after detoxification with 
buprenorphine.27 In the current study, 52% of 
subjects detoxified with clonidine and 53.5% of 
subjects detoxified with buprenorphine entered 
the maintenance treatment. The days remaining 
in therapy and the withdrawal from drug abuse 
was not significantly different in a 6-month 
follow-up. A study conducted by O’connor et al 
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reported that withdrawal from drug abuse in 
three drug groups receiving clonidine, clonidine 
with naltrexone and buprenorphine was not 
significantly related to the types of drug used for 
detoxification which is in agreement with the 
results of our study.7 Ling et al also suggested that 
regardless of the type of drug used for 
detoxification of heroine, the rate of recurrence of 
drug abuse is almost identical.28 The two main 
limitations to this study was the relatively small 
volume of samples which is justified considering 
the difficulty in obtaining the samples with the 
required characteristics and the lack of 
cooperation from patients at the follow-up period 
after detoxification which made it sometimes 
impossible to contact some patients. With respect 
to maintaining the treatment with the use of 
naltrexone, our results were in agreement with 
other investigations avoiding non-drug methods 
including Vining et al29 and also Bearn et al30 but 
success rate was lower compared to studies 
involving non-drug programs such as group 
therapy, family therapy or socio-therapy. This 
shows the advantage of these methods in 
controlling the signs of opioid withdrawal. Thus, 
the main disadvantage of naltrexone 
consumption may be the lack of a mechanism to 
induce patients to continue taking the drug.9 
Although the rate of recurrence was considerably 
high in this study, it could be due to the nature of 
the disease which is associated with high 
recurrence9 or the limitations of the study. It may 
be better to use non-drug programs in addition to 
the use of naltrexone. 
Although buprenorphine has been more 
effective than clonidine in controlling the 
withdrawal syndrome in this study, the method 
of detoxification applied did not significantly 
affect the results of withdrawal maintenance. 
Perhaps it is better to choose the method of 
detoxification on the basis of patient’s physical 
condition, patient’s desire, available facilities, 
treatment expenses and clinical judgment of the 
physician. In order to appropriately maintain the 
treatment and decrease the rate of recurrence 
following detoxification, naltrexone should be 
administered in addition to sufficient control and 
observation along with consideration of the 
personal, psychological and community factors. It 
is suggested that in subsequent studies in 
addition to naltrexone consumption, non-drug 
programs such as individual psychotherapy, 
behavior therapy, cognitive therapy, family 
therapy, supportive groups and social skill 
training also be taken into account. The 
maintenance treatment of addiction coupled with 
strict community supervision probably obtains 
more appropriate therapeutic results. 
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  88/01/81 :ﺗﺎرﻳﺦ درﻳﺎﻓﺖ
  98/1/03:ﺗﺎرﻳﺦ ﭘﺬﻳﺮش
ﻣﻘﺎﻳﺴﻪ ﻛﺎرآﻳﻲ ﺑﻮﭘﺮﻧﻮرﻓﻴﻦ و ﻛﻠﻮﻧﻴﺪﻳﻦ در ﺳﻢ زداﻳﻲ اﻓﺮاد واﺑﺴﺘﻪ 
  ﺑﻪ ﻫﺮوﺋﻴﻦ و درﻣﺎن ﻧﮕﻬﺪارﻧﺪه ﭘﺲ از آن
  
  ***ﻧﻮذر ﻧﺨﻌﻲدﻛﺘﺮ  ،**دﻛﺘﺮ ﻣﻨﺼﻮره ﻧﺼﻴﺮﻳﺎن، *دﻛﺘﺮ ﺣﺴﻦ ﺿﻴﺎءاﻟﺪﻳﻨﻲ
  
 .ﻋﻠﻮم ﭘﺰﺷﻜﻲ ﻛﺮﻣﺎن، ﻛﺮﻣﺎن، اﻳﺮان ﭘﺰﺷﻚ و ﻋﻀﻮ ﻣﺮﻛﺰ ﺗﺤﻘﻴﻘﺎت ﻋﻠﻮم اﻋﺼﺎب، داﻧﺸﮕﺎه روان *
  .ﭘﺰﺷﻚ، داﻧﺸﻜﺪه ﭘﺰﺷﻜﻲ، داﻧﺸﮕﺎه ﻋﻠﻮم ﭘﺰﺷﻜﻲ ﻛﺮﻣﺎن، ﻛﺮﻣﺎن، اﻳﺮان روان **
  .داﻧﺸﻴﺎر، ﮔﺮوه ﭘﺰﺷﻜﻲ اﺟﺘﻤﺎﻋﻲ، داﻧﺸﻜﺪه ﭘﺰﺷﻜﻲ، داﻧﺸﮕﺎه ﻋﻠﻮم ﭘﺰﺷﻜﻲ ﻛﺮﻣﺎن، ﻛﺮﻣﺎن، اﻳﺮان  ***
  
  :ﻣﻘﺪﻣﻪ
  ﭼﻜﻴﺪه
ﻳﻲ ﺑﺎ دو روش اﺳﺘﻔﺎده از ﺑﻮﭘﺮﻧﻮرﻓﻴﻦ زﻳﺮزﺑﺎﻧﻲ و اﻳﻦ ﻣﻄﺎﻟﻌﻪ ﺑﻪ ﻣﻘﺎﻳﺴﻪ ﻣﻴﺰان ﻣﻮﻓﻘﻴﺖ آﻣﻴﺰ ﺑﻮدن ﺳﻢ زدا
ﻛﻠﻮﻧﻴﺪﻳﻦ در ﺳﻢ زداﻳﻲ اﻓﺮاد واﺑﺴﺘﻪ ﺑﻪ ﻫﺮوﺋﻴﻦ و درﻣﺎن ﻧﮕﻬﺪارﻧﺪه ﭘﺲ از آن و ﺳﭙﺲ ارزﻳﺎﺑﻲ ﻣﻴﺰان 
  .ﺧﺖﭘﺮداﮔﻴﺮي ﺷﺶ ﻣﺎﻫﻪ در ﺑﻴﻤﺎران ﺑﺎ ﻣﺼﺮف ﻧﺎﻟﺘﺮﻛﺴﻮن  ﻋﻮد ﻣﺼﺮف ﻣﻮاد در ﻳﻚ ﭘﻲ
ﺑﺮ روي اﻓﺮاد  6831–88ﻫﺎي  ﭘﺰﺷﻜﻲ ﻛﺮﻣﺎن در ﺧﻼل ﺳﺎل روانﺳﻮﻛﻮر در ﺑﻴﻤﺎرﺳﺘﺎن  ﻛﺎرآزﻣﺎﻳﻲ دواﻳﻦ   :ﻫﺎ روش
اﻳﻦ اﻓﺮاد ﺑﺎ روش ﻧﻤﻮﻧﻪ ﮔﻴﺮي ﺗﺼﺎدﻓﻲ در  ؛ﺟﺴﺘﺠﻮي درﻣﺎن ﺳﻢ زداﻳﻲ اﻧﺠﺎم ﺷﺪدر واﺑﺴﺘﻪ ﺑﻪ ﻫﺮوﺋﻴﻦ 
ﻫﺮ روش ﺑﺎ اﺳﺘﻔﺎده از و ﻣﻮﻓﻘﻴﺖ ﺳﻢ زداﻳﻲ ﺑﺎ  ﻗﺮار ﮔﺮﻓﺘﻨﺪدو ﮔﺮوه درﻳﺎﻓﺖ ﻛﻨﻨﺪه ﻛﻠﻮﻧﻴﺪﻳﻦ و ﺑﻮﭘﺮﻧﻮرﻓﻴﻦ 
ﮔﺮم ﻧﺎﻟﺘﺮﻛﺴﻮن  ﻣﻴﻠﻲ 52ﺳﭙﺲ ﺑﻴﻤﺎران ﺑﺎ ﻣﺼﺮف روزاﻧﻪ  .در ﭘﺎﻳﺎن دوره ارزﻳﺎﺑﻲ ﺷﺪﻣﺼﺮف ﻧﺎﻟﺘﺮﻛﺴﻮن 
  .ﮔﻴﺮي ﺷﺪﻧﺪ ﻣﺎه از ﻧﻈﺮ اداﻣﻪ ﻣﺼﺮف ﻧﺎﻟﺘﺮﻛﺴﻮن و ﻋﺪم ﻣﺼﺮف ﻣﻮاد ﭘﻲ 6ﺑﺮاي  ،ﺗﺮﺧﻴﺺ ﺷﺪه
ﻣﻮﻓﻘﻴﺖ آﻣﻴﺰ ﺑﻮدن ﺳﻢ زداﻳﻲ ﺑﺎ ﻣﺼﺮف ﻧﺎﻟﺘﺮﻛﺴﻮن در ﺗﻤﺎﻣﻲ . ﻧﻔﺮ وارد ﻣﻄﺎﻟﻌﻪ ﺷﺪﻧﺪ 94ﺑﻪ ﻃﻮر ﻛﻠﻲ   :ﻫﺎ ﻳﺎﻓﺘﻪ
ارزﻳﺎﺑﻲ ﺑﺎﻟﻴﻨﻲ ﺑﺎزﮔﻴﺮي  ﻣﻴﺎﻧﮕﻴﻦ( درﺻﺪ 9/5)ﺎﻓﺖ ﻛﻨﻨﺪه ﻛﻠﻮﻧﻴﺪﻳﻦ، دو ﻧﻔﺮ در ﮔﺮوه درﻳ. ﻴﺪ ﮔﺮدﻳﺪﺄﻳﻓﺮاد ﺗا
داﺷﺘﻨﺪ  21روز ﭘﻨﺠﻢ ﺑﻴﺶ از ( elacs lawardhtiW etaipO lacinilCﻳﺎ  SWOC) از اﭘﻴﻮﺋﻴﺪ
ﺷﺘﻨﺪ ﻧﺪا 21ﭘﻨﺠﻢ ﺑﻴﺶ از  روز SWOCو در ﮔﺮوه درﻳﺎﻓﺖ ﻛﻨﻨﺪه ﺑﻮﭘﺮﻧﻮرﻓﻴﻦ، ﻫﻴﭽﻜﺪام ﻣﻴﺎﻧﮕﻴﻦ 
ﻫﺎي ذﻫﻨﻲ ﺗﺮك و ﻣﻴﻞ ﺑﻪ ﻣﺼﺮف ﻣﻮاد در ﻫﺮ دو ﮔﺮوه ﺑﺎ  ﻣﻴﺎﻧﮕﻴﻦ ﻋﻼﺋﻢ ﻋﻴﻨﻲ و ﻧﺸﺎﻧﻪ .(P=  0/681)
درﺻﺪ اﻓﺮاد  93درﺻﺪ اﻓﺮاد ﺳﻢ زداﻳﻲ ﺷﺪه ﺑﺎ ﻛﻠﻮﻧﻴﺪﻳﻦ و  91. ﮔﺬر زﻣﺎن ﻛﺎﻫﺶ ﻣﺸﺨﺺ داﺷﺖ
درﺻﺪ  25ﺑﺎ ﺑﻮﭘﺮﻧﻮرﻓﻴﻦ ﻣﺼﺮف ﻧﺎﻟﺘﺮﻛﺴﻮن را ﺑﻪ ﻃﻮر ﻣﺘﻮﺳﻂ ﺑﺮاي ﻳﻚ ﻣﺎه اداﻣﻪ دادﻧﺪ و  زداﻳﻲ ﺷﺪه ﺳﻢ
درﺻﺪ اﻓﺮاد ﺳﻢ زداﻳﻲ ﺷﺪه ﺑﺎ ﺑﻮﭘﺮﻧﻮرﻓﻴﻦ وارد درﻣﺎن ﻧﮕﻬﺪارﻧﺪه  35/5زداﻳﻲ ﺷﺪه ﺑﺎ ﻛﻠﻮﻧﻴﺪﻳﻦ و  اﻓﺮاد ﺳﻢ
در دو  ﻪﺎﻫﮔﻴﺮي ﺷﺶ ﻣ ﭘﻲ ﻣﺎﻧﺪن در درﻣﺎن و ﻋﺪم ﻋﻮد ﻣﺼﺮف ﻣﻮاد در ﻣﻴﺎﻧﮕﻴﻦ روزﻫﺎي ﺑﺎﻗﻲ .ﮔﺮدﻳﺪﻧﺪ
  .داري ﻧﺪاﺷﺖ ﮔﺮوه از ﻧﻈﺮ آﻣﺎري ﺗﻔﺎوت ﻣﻌﻨﻲ
ﻧﺸﺎﻧﮕﺎن  ﻋﻮارضﺛﺮﺗﺮي ﻧﺴﺒﺖ ﺑﻪ ﻛﻠﻮﻧﻴﺪﻳﻦ ﻋﻼﺋﻢ و ﺆﺗﺠﻮﻳﺰ ﺑﻮﭘﺮوﻧﻮرﻓﻴﻦ ﻃﻲ ﭼﻨﺪ روز ﺑﻪ ﻃﻮر ﻣ  :ﮔﻴﺮي ﻧﺘﻴﺠﻪ
  .ﻛﻨﺪ وﻟﻲ ﻣﻴﺰان ﻋﻮد ﻣﺼﺮف ﻣﻮاد در دو ﮔﺮوه ﺗﻔﺎوت ﺑﺎرزي ﻧﺪارد ﻣﺤﺮوﻣﻴﺖ از ﻣﻮاد را ﻛﻨﺘﺮل ﻣﻲ
  .، ﺑﻮﭘﺮﻧﻮرﻓﻴﻦ، ﻧﺎﻟﺘﺮﻛﺴﻮن، ﺳﻢ زداﻳﻲ ﻫﺮوﺋﻴﻦ، ﻋﻮدﻛﻠﻮﻧﻴﺪﻳﻦ  :واژﮔﺎن ﻛﻠﻴﺪي
  :ﺗﻌﺪاد ﺻﻔﺤﺎت
  :ﻫﺎ ﺗﻌﺪاد ﺟﺪول
  :ﺗﻌﺪاد ﻧﻤﻮدارﻫﺎ
  :ﺗﻌﺪاد ﻣﻨﺎﺑﻊ
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  .داﻧﺸﻜﺪه ﻋﻠﻮم ﭘﺰﺷﻜﻲ، داﻧﺸﮕﺎه ﻋﻠﻮم ﭘﺰﺷﻜﻲ ﻛﺮﻣﺎن، ﻛﺮﻣﺎن، اﻳﺮان و ﻣﺮﻛﺰ ﺗﺤﻘﻴﻘﺎت ﻋﻠﻮم اﻋﺼﺎب دﻛﺘﺮ ﺣﺴﻦ ﺿﻴﺎءاﻟﺪﻳﻨﻲ،  :ولﺆﻣﺴ آدرس ﻧﻮﻳﺴﻨﺪه
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